Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus pharmacokinetics in the first days after heart and lung transplantation
NL-OMON20956Phase 4Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- May 2013
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in graft rejection, sponsored by University Medical Center Utrecht. Primary endpoints: Whole blood total tacrolimus concentrations, Unbound tacrolimus plasma concentrations and 8 more. Started May 2013; status: active, not recruiting.
02
Drugs
tacrolimus
03
Conditions
graft rejection
Beyond the preview
Go deeper on NL-OMON20956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20956.